146 related articles for article (PubMed ID: 27416839)
1. ActRIIB blockade increases force-generating capacity and preserves energy supply in exercising mdx mouse muscle in vivo.
Béchir N; Pecchi E; Vilmen C; Le Fur Y; Amthor H; Bernard M; Bendahan D; Giannesini B
FASEB J; 2016 Oct; 30(10):3551-3562. PubMed ID: 27416839
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial impairment induced by postnatal ActRIIB blockade does not alter function and energy status in exercising mouse glycolytic muscle in vivo.
Béchir N; Pecchi É; Relizani K; Vilmen C; Le Fur Y; Bernard M; Amthor H; Bendahan D; Giannesini B
Am J Physiol Endocrinol Metab; 2016 Apr; 310(7):E539-49. PubMed ID: 26837807
[TBL] [Abstract][Full Text] [Related]
3. Activin type IIB receptor blockade does not limit adenosine triphosphate supply in mouse skeletal muscle in Vivo.
Béchir N; Pecchi É; Vilmen C; Bernard M; Bendahan D; Giannesini B
Muscle Nerve; 2018 Dec; 58(6):834-842. PubMed ID: 30025155
[TBL] [Abstract][Full Text] [Related]
4. Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy.
Puolakkainen T; Ma H; Kainulainen H; Pasternack A; Rantalainen T; Ritvos O; Heikinheimo K; Hulmi JJ; Kiviranta R
BMC Musculoskelet Disord; 2017 Jan; 18(1):20. PubMed ID: 28103859
[TBL] [Abstract][Full Text] [Related]
5. Exercise restores decreased physical activity levels and increases markers of autophagy and oxidative capacity in myostatin/activin-blocked mdx mice.
Hulmi JJ; Oliveira BM; Silvennoinen M; Hoogaars WM; Pasternack A; Kainulainen H; Ritvos O
Am J Physiol Endocrinol Metab; 2013 Jul; 305(2):E171-82. PubMed ID: 23695214
[TBL] [Abstract][Full Text] [Related]
6. Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy.
Pistilli EE; Bogdanovich S; Goncalves MD; Ahima RS; Lachey J; Seehra J; Khurana T
Am J Pathol; 2011 Mar; 178(3):1287-97. PubMed ID: 21356379
[TBL] [Abstract][Full Text] [Related]
7. Postnatal Hyperplasic Effects of ActRIIB Blockade in a Severely Dystrophic Muscle.
Nielsen C; Potter RM; Borowy C; Jacinto K; Kumar R; Carlson CG
J Cell Physiol; 2017 Jul; 232(7):1774-1793. PubMed ID: 27859236
[TBL] [Abstract][Full Text] [Related]
8. Myostatin/activin blocking combined with exercise reconditions skeletal muscle expression profile of mdx mice.
Kainulainen H; Papaioannou KG; Silvennoinen M; Autio R; Saarela J; Oliveira BM; Nyqvist M; Pasternack A; 't Hoen PA; Kujala UM; Ritvos O; Hulmi JJ
Mol Cell Endocrinol; 2015 Jan; 399():131-42. PubMed ID: 25304272
[TBL] [Abstract][Full Text] [Related]
9. Blockade of ActRIIB signaling triggers muscle fatigability and metabolic myopathy.
Relizani K; Mouisel E; Giannesini B; Hourdé C; Patel K; Morales Gonzalez S; Jülich K; Vignaud A; Piétri-Rouxel F; Fortin D; Garcia L; Blot S; Ritvos O; Bendahan D; Ferry A; Ventura-Clapier R; Schuelke M; Amthor H
Mol Ther; 2014 Aug; 22(8):1423-1433. PubMed ID: 24861054
[TBL] [Abstract][Full Text] [Related]
10. Combined effect of AAV-U7-induced dystrophin exon skipping and soluble activin Type IIB receptor in mdx mice.
Hoogaars WM; Mouisel E; Pasternack A; Hulmi JJ; Relizani K; Schuelke M; Schirwis E; Garcia L; Ritvos O; Ferry A; 't Hoen PA; Amthor H
Hum Gene Ther; 2012 Dec; 23(12):1269-79. PubMed ID: 22894762
[TBL] [Abstract][Full Text] [Related]
11. Contractile efficiency of dystrophic mdx mouse muscle: in vivo and ex vivo assessment of adaptation to exercise of functional end points.
Capogrosso RF; Mantuano P; Cozzoli A; Sanarica F; Massari AM; Conte E; Fonzino A; Giustino A; Rolland JF; Quaranta A; De Bellis M; Camerino GM; Grange RW; De Luca A
J Appl Physiol (1985); 2017 Apr; 122(4):828-843. PubMed ID: 28057817
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment with a soluble activin type IIB receptor/Fc fusion protein improves hypoxia-induced muscle dysfunction.
Pistilli EE; Bogdanovich S; Mosqueira M; Lachey J; Seehra J; Khurana TS
Am J Physiol Regul Integr Comp Physiol; 2010 Jan; 298(1):R96-R103. PubMed ID: 19864340
[TBL] [Abstract][Full Text] [Related]
13. Soluble activin receptor type IIB increases forward pulling tension in the mdx mouse.
George Carlson C; Bruemmer K; Sesti J; Stefanski C; Curtis H; Ucran J; Lachey J; Seehra JS
Muscle Nerve; 2011 May; 43(5):694-9. PubMed ID: 21462203
[TBL] [Abstract][Full Text] [Related]
14. Lack of myostatin impairs mechanical performance and ATP cost of contraction in exercising mouse gastrocnemius muscle in vivo.
Giannesini B; Vilmen C; Amthor H; Bernard M; Bendahan D
Am J Physiol Endocrinol Metab; 2013 Jul; 305(1):E33-40. PubMed ID: 23632633
[TBL] [Abstract][Full Text] [Related]
15. Effects of PDE5 inhibition on dystrophic muscle following an acute bout of downhill running and endurance training.
Batra A; Vohra RS; Chrzanowski SM; Hammers DW; Lott DJ; Vandenborne K; Walter GA; Forbes SC
J Appl Physiol (1985); 2019 Jun; 126(6):1737-1745. PubMed ID: 30946638
[TBL] [Abstract][Full Text] [Related]
16. Administration of a soluble activin type IIB receptor promotes the transplantation of human myoblasts in dystrophic mice.
Fakhfakh R; Lee SJ; Tremblay JP
Cell Transplant; 2012; 21(7):1419-30. PubMed ID: 22449443
[TBL] [Abstract][Full Text] [Related]
17. Interference with myostatin/ActRIIB signaling as a therapeutic strategy for Duchenne muscular dystrophy.
Amthor H; Hoogaars WM
Curr Gene Ther; 2012 Jun; 12(3):245-59. PubMed ID: 22554312
[TBL] [Abstract][Full Text] [Related]
18. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.
Morvan F; Rondeau JM; Zou C; Minetti G; Scheufler C; Scharenberg M; Jacobi C; Brebbia P; Ritter V; Toussaint G; Koelbing C; Leber X; Schilb A; Witte F; Lehmann S; Koch E; Geisse S; Glass DJ; Lach-Trifilieff E
Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12448-12453. PubMed ID: 29109273
[TBL] [Abstract][Full Text] [Related]
19. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.
St Andre M; Johnson M; Bansal PN; Wellen J; Robertson A; Opsahl A; Burch PM; Bialek P; Morris C; Owens J
Skelet Muscle; 2017 Nov; 7(1):25. PubMed ID: 29121992
[TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of voluntary wheel running on the properties of dystrophic mouse muscle.
Hayes A; Williams DA
J Appl Physiol (1985); 1996 Feb; 80(2):670-9. PubMed ID: 8929614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
